Grants for City or township governments - Federal

This funding opportunity supports interdisciplinary research centers focused on advancing the understanding and treatment of communication disorders, such as hearing and speech issues, through collaborative projects and clinical trials.

This funding opportunity supports advanced pre-clinical research projects that utilize nanotechnology to improve cancer treatment and diagnostics, aiming to transition these innovations toward clinical applications.

This funding opportunity supports early-career researchers in the U.S. to develop their skills in implementation science for effective substance use prevention and treatment, enabling them to lead clinical trials that address the opioid crisis.

This funding opportunity supports projects that preserve Kenya's cultural heritage, including historic sites, museum collections, and traditional practices, targeting eligible educational institutions, NGOs, and organizations dedicated to cultural preservation.

This funding opportunity provides significant financial support to U.S. higher education institutions and research organizations with established HIV/AIDS research programs, enabling them to enhance their research infrastructure and foster interdisciplinary collaboration in the fight against HIV/AIDS.

This grant provides funding to various organizations and governments for projects that protect and restore habitats for neotropical migratory birds across the Americas, with a strong emphasis on international collaboration and partner contributions.

The Office of Minority Health announces the anticipated availability of funds for Fiscal Year (FY) 2025 under the authority of 42 U.S.C. 300u-6 (Section 1707 of the Public Health Service Act) for a demonstration project that supports the development of a National Coordinating Center for Language Access Services . Demonstration projects are time-limited projects for the purpose of assessing the effectiveness of an approach or intervention toward reaching a desired outcome. We expect award recipients under this opportunity to consider approaches to sustainability beyond the end of the support provided by OMH.Individuals with limited English proficiency face barriers to health care and social services that increase their risk for poor health outcomes. We intend for the funded project to create a National Coordinating Center to connect health and human service professionals with qualified health language interpreters and translators to improve access to language services for individuals limited English proficiency. The funded project will develop technical components needed to host the Center, connect and engage a collaborative network of community-based organizations, and promote the Center nationally to health and human service organizations and agencies. OMH also expects the project to address gaps in access to language services and improve the quality of care and health outcomes for individuals with limited English proficiency. Eligible applicants include any private nonprofit or public entity located in a State. State includes, in addition to the several States, only the District of Columbia, Guam, the Commonwealth of Puerto Rico, the Northern Mariana Islands, the Virgin Islands, American Samoa, the Trust Territory of the Pacific Islands, and any agency or instrumentality thereof exclusive of local governments. (42 U.S.C. 201(f) (PHS Act, Section 2(f)), 45 C.F.R. 75.2). Eligible entities include private nonprofit or public faith-based organizations, community-based organizations, and American Indian/Alaska Native/Native American (AI/AN/NA) organizations. Applications must be submitted through Grants.gov, and applicants must have an active SAM.gov registration when submitting an application. Interested applicants are strongly encouraged begin the registration process for both systems early.

This funding opportunity provides financial support to research institutions for developing and sharing essential resources to advance the study of Polycystic Kidney Disease, fostering collaboration and innovation in the field.

This funding opportunity provides financial support to public and nonprofit organizations for managing fire science exchanges that deliver critical fire management information to stakeholders in six specific regions across the United States.

This modification (000001) includes: -FOA includes the addition of Section IV.A.ii (Applicant Education Services) This FOA solicits proposals for RD associated with Scalable Concentrating Solar Collectors, Scalable Supercritical Carbon Dioxide (sCO2) and Scalable Concentrating Solar-thermal Receivers and Reactors. The three technologies will support the government-wide approach to the climate crisis by driving the innovation that can lead to the deployment of clean energy technologies, which are critical for climate protection.

The FY24 PCRP Physician Research Award supports a mentored research experience to prepare physicians with clinical duties and/or responsibilities for productive careers in prostate cancer research. The mentored physician is considered the Principal Investigator (PI) of the application. This award emphasizes equally the quality of the proposed research project and the career development of the PI, which should prepare physicians for careers in basic, population science, translational, or clinical prostate cancer research. All applications for the FY24 PCRP Physician Research Award are to be written by the PI, with appropriate direction from the mentor(s).Key elements of this award mechanism are as follows: Principal Investigator: Physicians with clinical duties and/or responsibilities who, at the application submission deadline, are either in the last year of an accredited graduate medical education program as a resident or fellow or within 5 years of having initiated a faculty appointment (including Instructor positions) are eligible to apply. The PI must demonstrate a commitment to a career as a physician-scientist and investigator at the forefront of prostate cancer research and clinical practice; however, the PI is not required to have previous prostate cancer research experience. The award is intended to provide protection of the PIs time for prostate cancer research. Applications are strongly encouraged to demonstrate protection of at least 20% of the PIs time for prostate cancer research, which is not required to be exclusive to this award but can include effort dedicated to other prostate cancer research projects. Mentor(s): This award requires the involvement of at least one designated mentor with an established research program in prostate cancer, as evidenced by recent publications, active funding, and successful mentorship. In addition, the mentor(s) must demonstrate a commitment to advancing the PIs career in prostate cancer research. Research Approach: Proposed research ideas are required to address one or more of the FY24 PCRP Overarching Challenges. The scientific rationale and experimental methodology should demonstrate in-depth analysis of the research problem presented. The feasibility of the research design and methods should be well defined, and a clear plan should be articulated as to how the proposed goals of the project can be achieved. The inclusion of preliminary data relevant to prostate cancer and the proposed project is encouraged but not required. Any preliminary data provided should be from the PI, mentor(s), or member(s) of the collaborating team. Additionally, required resources should be identified and supported through documentation. Research involving human subjects is permitted under this funding opportunity but is restricted to studies without clinical trials. Correlative studies associated with an existing clinical trial are particularly encouraged, provided they are determined to be no greater than minimal risk by the Institutional Review Board (IRB) of record and the USAMRDC Office of Human and Animal Research Oversight (OHARO), Office of Human Research Oversight. Researcher Development Plan: An individualized researcher development plan is required and should be prepared with appropriate guidance from the mentor(s). The researcher development plan should include a clearly articulated strategy for acquiring the necessary skills, competence, and expertise that will enable the PI to successfully complete the proposed research project and foster the PIs development as an independent prostate cancer physician-scientist. An environment appropriate to the proposed mentoring and research project must be clearly described, although any deficiencies of resources and/or mentorship at the PIs institution can be mitigated through collaboration(s) with other institutions. If the PI will be utilizing resources at another institution to successfully complete the proposed project, then the PI is strongly encouraged to designate a co-mentor at the collaborating institution. Impact: The proposed research must address and provide a solution to one or more of the FY24 PCRP Overarching Challenges and ultimately should have the potential to make a significant impact on the programs mission of eliminating death and suffering from prostate cancer and enhancing the well-being of Service Members and their Families, Veterans, and all the patients and caregivers who are experiencing the impact of the disease.Investigators are strongly encouraged to incorporate the following components into their study design, where appropriate, in order to maximize the potential impact of the proposed research project: authentication of proposed cell lines; statistical rigor of preclinical animal experiments; and incorporation of experiments to assess clinical relevance and translatability of findings. Studies utilizing data that are derived from large patient studies that include long-term health records, biospecimen repositories, and pre-existing research and apply state-of-the-art genomic and/or proteomic analysis, bioinformatics, and/or mathematical models to such data are also encouraged. Investigators are highly encouraged to provide a letter of support indicating access to and the availability of any resources required to support the study.A congressionally mandated Metastatic Cancer Task Force was formed with the purpose of identifying ways to help accelerate clinical and translational research aimed at extending the lives of advanced state and recurrent patients. As a member of the Metastatic Cancer Task Force, the CDMRP encourages applicants to review the recommendations (https://health.mil/Reference-Center/Congressional-Testimonies/2018/05/03/Metastatic-Cancer-Research) and submit research ideas to address these recommendations provided they are within the limitations of this funding opportunity and fit within the FY24 PCRP priorities.Innovative research involving nuclear medicine and related techniques to support early diagnosis, more-effective treatment, and improved health outcomes of active-duty Service Members and their Families is encouraged. Such research could improve diagnostic and targeted treatment capabilities through noninvasive techniques and may drive the development of precision imaging and advanced targeted therapies.Applications from investigators within the military services and applications involving multidisciplinary collaborations among academia, industry, the military services, the U.S. Department of Veterans Affairs (VA), and other federal government agencies are highly encouraged. These relationships can leverage knowledge, infrastructure, and access to unique clinical populations that the collaborators bring to the research effort, ultimately advancing research that is of significance to Service Members, Veterans, and/or their Families. If the proposed research relies on access to unique resources or databases, the application must describe the access at the time of submission and include a plan for maintaining access as needed throughout the proposed research.All projects should adhere to a core set of standards for rigorous study design and reporting to maximize the reproducibility and translational potential of clinical and preclinical research. The standards are described in SC Landis et al., 2012, A call for transparent reporting to optimize the predictive value of preclinical research, Nature 490:187-191 (https://www.nature.com/nature/ journal/v490/n7419/full/nature11556.html. While these standards are written for preclinical studies, the basic principles of randomization, blinding, sample-size estimation, and data handling derive from well-established best practices in clinical studies.Clinical trials are not allowed. A clinical trial is defined in the Code of Federal Regulations, Title 45, Part 46.102 (45 CFR 46.102) as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include a placebo or another control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes.Studies that do not seek to measure safety, effectiveness, and/or efficacy outcome(s) of an intervention are not considered clinical trials.For the purposes of this funding opportunity, research that meets the definition of a clinical trial is distinct from clinical research. Clinical research encompasses research with human data, human specimens, and/or interaction with human subjects. Clinical research is observational in nature and includes:(1) Research conducted with human subjects and/or material of human origin such as data, specimens, and cognitive phenomena for which an investigator (or co-investigator) does not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention. Research meeting this definition may include but is not limited to: (a) mechanisms of human disease, (b) diagnostic or detection studies (e.g., biomarker or imaging), (c) health disparity studies, and (d) development of new technologies.(2) Epidemiologic and behavioral studies that do not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention.(3) Outcomes research and health services research that do not fit under the definition of clinical trial.Excluded from the definition of clinical research are in vitro studies that utilize human data or specimens that cannot be linked to a living individual and meet the requirements for exemption under 46.104(d)(4) of the Common Rule.The funding instrument for awards made under the program announcement will be grants (31 USC 6304).The anticipated direct costs budgeted for the entire period of performance for an FY24 PCRP PRA Award should not exceed $750,000. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.Awards supported with FY24 funds will be made no later than September 30, 2025.The CDMRP expects to allot approximately $4.80M to fund approximately four PCRP Physician Research Award applications. Funding of applications received is contingent upon the availability of federal funds for this program, the number of applications received, the quality and merit of the applications as evaluated by peer and programmatic review, and the requirements of the government. Funds to be obligated on any award resulting from this funding opportunity will be available for use for a limited time period based on the fiscal year of the funds. It is anticipated that awards made from this FY24 funding opportunity will be funded with FY24 funds, which will expire for use on September 30, 2030.

This funding opportunity supports research and evaluation projects that address the needs of special populations in corrections, improve workforce management, and enhance correctional culture and safety, inviting a wide range of organizations to collaborate on innovative solutions.

This grant provides funding for early-career researchers to conduct health-related studies that benefit individuals affected by the September 11, 2001, terrorist attacks, focusing on improving diagnosis and treatment for various health issues.

This funding opportunity provides financial support for a wide range of organizations and individuals to implement critical recovery actions for endangered and threatened species across the United States.

This grant provides funding to neuroscience researchers to advance their small molecule drug discovery and development projects aimed at treating disorders of the nervous system.

This funding opportunity provides financial support for projects focused on ecosystem restoration and environmental resilience in American Samoa, Guam, the Northern Mariana Islands, and the U.S. Virgin Islands, targeting local governments, educational institutions, and nonprofits serving these areas.

This funding opportunity supports academic and industrial partnerships to develop new vaccines aimed at preventing tuberculosis infection and disease, addressing the urgent need for effective solutions against rising TB rates.

This funding opportunity provides financial support to various organizations to assist the Botswana Ministry of Health in implementing effective HIV prevention and treatment programs, particularly for underserved populations.

The "Genetic Architecture of Mental Disorders in Ancestrally Diverse Populations II" grant aims to expand the existing mental health research network to include larger studies, provide guidance to the scientific community, and support career development for researchers from low-resource settings worldwide.

This funding opportunity supports early-career scientists in the U.S. who are focused on conducting impactful research to improve worker health and safety in various industries.